| Literature DB >> 32839950 |
Valentina Delle Donne1, Nicoletta Ciccarelli2, Valentina Massaroni1, Alberto Borghetti3, Alex Dusina1, Damiano Farinacci1, Elena Visconti3, Enrica Tamburrini1,3, Massimiliano Fabbiani4, Simona Di Giambenedetto1,3.
Abstract
Everyday functioning (EF) impairment is frequent in people living with HIV (PLWH). Our aim was to better explore EF and its association with PLWH cognition, by administering both the IADL scale, the most common functional scale, and a new and ecologic multi-domain (communication and financial skills) tool to measure EF as the University of California San Diego (UCSD) Performance-Based Skills Assessment-Brief Version (UPSA-B). Eighty-five PLWH on cART with very good immunological condition and 23 age- and education-matched healthy controls (HC) were enrolled. PLWH underwent a standardized neuropsychological battery plus IADL, and cognitive impairment was defined according to Frascati criteria. Both groups underwent the UPSA-B. Only 6 subjects (7%) were affected by cognitive impairment (asymptomatic profile). While IADL score was at ceiling for all patients, the UPSA-B total score was significantly worse in PLWH when compared with HC [mean 82.1 (SD 9.3) vs 89.2 (SD 6.2); p < 0.001]. At communication subtest, PLWH group and HC were significantly different (p = 0.002), while no difference emerged at financial skills (p = 0.096). Higher score at UPSA-B was independently associated with better global cognitive performance (composite Z-score) (β 7.79; p < 0.001). Also considering each single cognitive domain, UPSA-B performance (both total and at subtests) confirmed the association with neurocognitive performance. In conclusion, UPSA-B seems to better discriminate EF impairment than IADL in PLWH, and it was associated with cognitive functions, also in the absence of symptomatic cognitive impairment. Thus, it appears a promising tool in the context of HIV infection to avoid misdiagnosis and to better detect also mild EF.Entities:
Keywords: Cognition evaluation; Everyday functioning; Functional assessment; HIV-associated neurocognitive disorders
Year: 2020 PMID: 32839950 PMCID: PMC7716816 DOI: 10.1007/s13365-020-00891-8
Source DB: PubMed Journal: J Neurovirol ISSN: 1355-0284 Impact factor: 2.643
Demographic and clinical characteristics of PLWH group and HC
| Parameters | PLWH ( | HC ( | |
|---|---|---|---|
| Male sex | 66 (78) | 11 (48) | |
| Age (years)* | 54 (48–60) | 53 (47–58) | 0.967 |
| Education (years)* | 13 (11–17) | 13 (12–17) | 0.951 |
| Smokers | 10 (12) | – | |
| Cannabis use | 2 (2.4) | – | |
| Alcohol use | 1 (1.2) | – | |
| Other drug use | 1 (1.2) | – | |
| Transmission risk factor | – | – | |
| Homosexual | 35 (44) | ||
| Heterosexual | 34 (43) | ||
| Injecting drug users | 10 (13) | ||
| Time from HIV diagnosis (years)* | 14 (4–24) | – | – |
| Time from first cART (years)* | 12 (4–20) | – | – |
| Time from current cART (years)* | 2 (0.9–2.7) | – | – |
| HIV-RNA < 50 copies/mL | 79 (96) | – | – |
| CD4 cell count (cell/μL)* | 551 (121–790) | – | – |
| CD4 nadir (cell/μL)* | 100 (6–270) | – | – |
Bold values represent statistically significant p values
N number, IQR interquartile range, PLWH people living with HIV, HC healthy control, cART combined antiretroviral therapy
*Median and IQR reported
Neuropsychological performances in each cognitive domain
| Cognitive domains | Mean Z-score (SD) | N (%) of patients with domain-specific impairmenta |
|---|---|---|
| Global Z-scoreb | 0.36 (0.63) | 4 (4.7%) |
| Memory | 0.39 (1.01) | 6 (7%) |
| Attention | 0.54 (0.77) | 3 (3.5%) |
| Executive functions | 0.12 (0.57) | 2 (2.4%) |
| Language | 0.72 (1.05) | 4 (4.7%) |
| Fine motor skills | 0.05 (1.12) | 11 (13%) |
N number, SD standard deviation
aBased on Italian normative data
bAverage of single Z-score on each domain
Factors associated to UPSA-B total score
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Mean change | 95% CI | Mean change | 95% CI | |||
| Age (per 10-year increase) | − 0.62 | − 0.25/0.12 | 0.519 | – | – | – |
| Education (per 1-year increase) | 0.71 | 0.16/1.27 | 0.18 | − 0.32/0.69 | 0.463 | |
| Sex (male versus female) | 1.86 | − 2.97/6.69 | 0.445 | – | – | – |
| Smoking | − 7.22 | − 13.29/− 1.15 | − 1.70 | − 7.35/3.94 | 0.549 | |
| Cannabis use | − 10.93 | − 24.05/2.18 | 0.101 | – | – | – |
| Alcohol use | − 4.22 | − 22.94/14.50 | 0.655 | – | – | – |
| Other drug use | 0.83 | − 17.91/19.58 | 0.930 | – | – | – |
| Years from HIV diagnosis (per 1-year increase) | 0.009 | − 0.09/0.11 | 0.869 | – | – | – |
| Time from starting first cART regimen (per 1-year increase) | 0.01 | − 0.13/0.15 | 0.853 | – | – | – |
| Time from starting current cART regimen (per 1-year increase) | 0.01 | − 0.07/0.19 | 0.724 | – | – | – |
| Adherence (per 10% increase) | 0.11 | − 0.01/0.24 | 0.075 | 0.07 | − 0.03/0.19 | 0.176 |
| Past AIDS-defining events | 1.43 | − 3.05/5.90 | 0.527 | – | – | – |
| CD4 cell count, cells/μL (per 100 cells/mL increase) | 0.00 | − 0.001/0.00 | 0.121 | – | – | – |
| CD4 cell count nadir, cells/μL (per 100 cells/mL increase) | 0.005 | − 0.007/0.1 | 0.411 | – | – | – |
| HIV RNA < 50 copies/mL | − 8.79 | − 19.74/2.15 | 0.114 | – | – | – |
| Injecting drug users | 1.98 | − 4.35/8.31 | 0.535 | – | – | – |
| Hepatitis co-infection | − 5.50 | − 14.2/3.1 | 0.211 | – | – | – |
| Zung Depression Scale (per 1 point increase) | −1.11 | − 0.38/0.15 | 0.389 | – | – | – |
| Mean Z-score SNB (per 1 Z-score increase) | 8.28 | 5.63/10.9 | 7.56 | 4.68/10.44 | ||
Bold values represent statistically significant p values
CI confidence interval, cART combined antiretroviral therapy, SNB Standardized Neuropsychological Battery test